TABLE 3.
Recent large published studies evaluating the prevalence of fusidic acid resistance in Staphylococcus aureusa
| Country(ies) | Authors (reference) | Yr(s) | Study setting or population | Prevalence of phenotypic resistance (no. of resistant isolates/no. of isolates tested [%]) |
Acquired resistance (no. of isolates with detected mutations) |
No. of isolates with detected fusA mutations | |||
|---|---|---|---|---|---|---|---|---|---|
| MSSA | MRSA | Overall | fusB | fusC | |||||
| Nine European countries | den Heijer et al. (316) | 2010–2011 | Nasal carriage isolates from primary care | 194/6,814 (2.8) | 9/91 (9.9) | 203/6,905 (2.9) | 48 | 88 | 52 |
| United States | Farrell et al. (150) | 2014 | Hospitals | 4/956 (0.4) | 0/848 | 0 | 3 | 1 | |
| New Zealand | Williamson et al. (108) | 2013 | Community | NR | NR | 147/500 (29.4) | 0 | 147 | NR |
| United States, Australia, and Canada | Castanheira et al. (125) | 2007–2008 | Hospital | NR | NR | 25/4,167 (0.6) | 4 | 13 | 3 |
| Thirteen European countries | Castanheira et al. (137) | 2008 | Hospital | NR | NR | 288/2,700 (10.7) | 34 | 57 | 56 |
| Denmark | McLaws et al. (317) | 2003–2005 | NR | NR | 291/1,639 (17.8) | 196 (inferred by authors from previous work) | 57 | 39 | |
| China | Liu et al. (134) | 2008–2009 | Children's hospitals | 2/120 (1.2) | 2/66 (3.0) | 4/186 (2.2) | 2 | 2 | NR |
| Greece | Souli et al. (318) | 2012–2013 | Hospitals | 81/808 (10.0) | 212/372 (57.0) | 293/1,180 (24.8) | NR | NR | NR |
| United States | Jones et al. (319) | 2008–2009 | Hospitals | 15/3,463 (0.4) | 11/3,876 (0.3) | 26/7,339 (0.4) | 3 | 12 | 5 |
| Australia | Coombs et al. (320) | 2014 | Hospitals | 74/1,791 (4.1) | 17/414 (4.1) | 91/2,205 (4.1) | NR | NR | NR |
| Australia | Coombs et al. (314) | 2012 | Community | 135/2,334 (5.8) | 26/510 (5.1) | 161/2,844 (5.7) | NR | NR | NR |
a
Abbreviations: MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant S. aureus; NR, not reported.